AstraZeneca Annual Report and Form 20-F Information 2008

Geographical review

2008 IN BRIEF

• Despite a continually challenging environment, including generic pressure, combined sales of Arimidex, Crestor, Nexium, Seroquel and Symbicort up 5% in the US – 65% of our total US sales.
• Maintained market position as the second largest brand name pharmaceutical company in Canada.
• Solid sales performance in the Rest of World, up 5%.
• Strong brand performance in Western Europe but intense competition and governmental controls over healthcare expenditure.
• Strong volume growth from key products, Crestor, Losec and Seroquel in Japan.
• Emerging Rest of World delivers strong sales growth, up 16% with Emerging Europe sales up 10% and Emerging Asia sales up 10%.
• Continued expansion in China, including continued sales growth up 31%.
• EU Commission of a Sectoral Inquiry into the pharmaceutical industry continues, with a final report expected in Spring 2009.

For more information regarding our products please refer to the relevant sections of the Therapy Area Review. Details of relevant continuing litigation can be found in Note 25 to the Financial Statements and details of relevant risks are set out in the Principal Risks and Uncertainties section.

For the AstraZeneca definition of markets please see the Glossary.

Back to the top